Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 1/20 | 0.48 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 7/20 | 0.45 |
| ▸ | SCN4A | P35499 | 1/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.43 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | LIPE | Q05469 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2955257 | 0.88 | KCNH2 (0.47) | CHRM4BCHEACHEEPHX1EPHX2 | |
| SCHEMBL3038315 | 0.88 | CARM1 (0.49) | CARM1PRMT6CHRM4BCHEACHE | |
| SCHEMBL2095960 | 0.87 | CARM1 (0.58) | CARM1PRMT6CHRM4SCN9ASCN4A | |
| SCHEMBL15441934 | 0.86 | GAA (0.48) | CHRM4BCHEACHELIPEKCNH2 | |
| SCHEMBL27154213 | 0.81 | BCHE (0.52) | CARM1PRMT6BCHEACHESCN9A | |
| SCHEMBL28786004 | 0.77 | CARM1 (0.59) | CARM1PRMT6CHRM4BCHEACHE | |
| SCHEMBL2357937 | 0.76 | KCNH2 (0.47) | BCHEACHEEPHX1EPHX2KCNH2 | |
| SCHEMBL19809288 | 0.76 | KCNH2 (0.47) | BCHEACHEEPHX1EPHX2KCNH2 | |
| SCHEMBL27779963 | 0.75 | CARM1 (0.52) | CARM1PRMT6CHRM4SCN9ASCN4A | |
| SCHEMBL13278969 | 0.74 | KCNH2 (0.53) | CARM1PRMT6CHRM4EPHX2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8552188-B2 | Epoxy compound and method for manufacturing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| US-20130072683-A1 | EPOXY COMPOUND AND METHOD FOR MANUFACTURING THE SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-21 | — | — | US | disclosed |
| US-8344148-B2 | Epoxy compound and method for manufacturing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-01 | — | — | US | disclosed |
| EP-2144899-B1 | EPOXY COMPOUND AND METHOD FOR MANUFACTURING THE SAME | OTSUKA PHARMA CO LTD (JP) | 2011-12-07 | — | — | EP | disclosed |
| US-20100217005-A1 | EPOXY COMPOUND AND METHOD FOR MANUFACTURING THE SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-08-26 | — | — | US | disclosed |
| EP-2144899-A1 | EPOXY COMPOUND AND METHOD FOR MANUFACTURING THE SAME | Otsuka Pharmaceutical Co., Ltd. (JP) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008140090-A1 | EPOXY COMPOUND AND METHOD FOR MANUFACTURING THE SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072683-A1 | EPOXY COMPOUND AND METHOD FOR MANUFACTURING THE SAME | SQLE, CYP2E1, CYP1A1 | CARM1 359/4885PRMT6 1134/4885CHRM4 2522/4885 |
| US-20100217005-A1 | EPOXY COMPOUND AND METHOD FOR MANUFACTURING THE SAME | SQLE, CYP2E1, CYP1A1 | CARM1 409/4885PRMT6 1210/4885CHRM4 2498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.